AstraZeneca will purchase FibroGen China for about $160 million to gain rights to FibroGen's Roxadustat anemia drug in China, FibroGen said Thursday.
Roxadustat is indicated for anemia in chronic kidney disease. It has a pending regulatory decision for chemotherapy-induced anemia, FibroGen said.
FibroGen will be entitled to an enterprise value of $85 million and about $75 million in net cash held in China.
The transaction is expected to close by the middle of 2025.
Following closing, FibroGen will also repay its term loan facility to investment funds managed by Morgan Stanley Tactical Value.
The purchase comes as AstraZeneca is facing probes in China following investments in the country, Reuters reported separately.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。